US Patent

US11013733 — Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)

Method of Use · Assigned to Forma Therapeutics Inc · Expires 2039-05-16 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating cancer patients with an IDH-1 mutation by administering a pharmaceutical composition containing Compound 1.

USPTO Abstract

Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Drugs covered by this patent

Rezlidhia (OLUTASIDENIB) · Rigel Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3496`	—	Rezlidhia

Patent Metadata

Patent number: US11013733
Jurisdiction: US
Classification: Method of Use
Expires: 2039-05-16
Drug substance claim: No
Drug product claim: No
Assignee: Forma Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.